May 27, 2020
Alkermes Highlights New Data From Schizophrenia Portfolio at the American Society of Clinical Psychopharmacology 2020 Annual Meeting
May 14, 2020
Alkermes Presents New Data From Schizophrenia Portfolio at Virtual 2020 Congress of the Schizophrenia International Research Society
Apr 29, 2020
Alkermes Plc Reports First Quarter 2020 Financial Results and Provides COVID-19 Related Business Update
Mar 04, 2020
Journal of Clinical Psychiatry Publishes Data from Alkermes' Phase 3 ENLIGHTEN-1 Efficacy Study of ALKS 3831 in Patients With Schizophrenia
Jan 28, 2020
Alkermes Announces U.S. Food and Drug Administration Acceptance of ALKS 3831 New Drug Application for Treatment of Schizophrenia and Bipolar I Disorder
Nov 19, 2019
Alkermes Submits New Drug Application to U.S. Food and Drug Administration for ALKS 3831 for Treatment of Schizophrenia and Bipolar I Disorder
Nov 04, 2019
Alkermes to Present Data From ALKS 4230 Clinical Development Program at the Society for Immunotherapy of Cancer's (SITC) 34th Annual Meeting
Oct 21, 2019
Alkermes Announces Clinical Collaboration With Fred Hutchinson Cancer Research Center for Novel Immuno-Oncology Drug Candidate ALKS 4230
Oct 07, 2019
Alkermes Presents New Health Economics and Outcomes Research on Patients With Schizophrenia and Bipolar I Disorder at 2019 Psych Congress
Jul 25, 2019
Alkermes Plc Reports Second Quarter 2019 Financial Results
Jul 15, 2019
Alkermes Expands Planned New Drug Application for ALKS 3831 to Include Treatment of Bipolar I Disorder
Apr 25, 2019
Alkermes Plc Reports First Quarter 2019 Financial Results
Apr 01, 2019
Alkermes to Present New ALKS 3831 Data From ENLIGHTEN-2 and Interim Extension Safety Study Results at 2019 Congress of the Schizophrenia International Research Society
Nov 29, 2018
Alkermes Announces Positive Topline Results From ENLIGHTEN-2 Phase 3 Study of ALKS 3831 in Patients With Schizophrenia
Oct 17, 2018
Alkermes Highlights Ongoing Commitment to Research and Innovation in Depression and Schizophrenia at 2018 Psych Congress
Jul 26, 2018
Alkermes Plc Reports Second Quarter 2018 Financial Results
May 23, 2018
Alkermes to Present Data on Depression and Schizophrenia Portfolios at Upcoming American Society of Clinical Psychopharmacology Annual Meeting
May 03, 2018
Alkermes to Host Webcast and Conference Call to Discuss ALKS 3831 Development Program
Apr 30, 2018
Alkermes to Present Clinical Data at Upcoming American Psychiatric Association Annual Meeting
Apr 26, 2018
Alkermes Completes Patient Enrollment in Pivotal Weight Study of ALKS 3831 for Schizophrenia